$EOLS News
Last published 1w ago
- 1w agoEOLSThird Quarter 2026 Earnings Conference Call - EVOLUS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for standing by. Welcome to Evalus' third quarter earnings conference call. As a reminder, today's conference is being recorded and webcast live. All participants are in a listen-o
- 1w agoEOLSEvolus, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoEOLSEvolus to Participate in Upcoming Investor Conferences in New York and LondonBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor
- 3w agoEOLSEvolus to Report Third Quarter Financial Results on November 4, 2026Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2026 financial results on Wednesday,
- 4w agoEOLSEvolus Expands Innovation Pipeline with Novel Injectable Hair Restoration ProgramBusiness WirePotential first-in-class injectable aesthetic procedure for hair restorationEarly-stage partnership advances Evolus’ business development strategy through a disciplined, capital-efficient approach to innovationEvolus,
- 1mo agoEOLSEvolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important CausesBusiness WireThe first initiative will support Look Good Feel Better® during Breast Cancer Awareness Month Evolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of
- 2mo agoCNXUESTAEOLSINMD+1A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to CapturePR NewswireEquity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare....
- 2mo agoTLXEOLSTelix Appoints David Gill as ChairGlobeNewswireDavid Gill appointed Chair of the Telix Board, effective immediately.Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.Dr. Mark Nelson will continue to serve on
- 3mo agoEOLSEvolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial OutlookBusiness WireGlobal Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets GAAP Operating Loss of $4.5
- 3mo agoEOLSEvolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New ZealandBusiness WireEstablishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets Further leverages Evolus’ international commercial infrastructure to
- 3mo agoEOLSEvolus to Report Second Quarter Financial Results on August 5, 2026Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday,
- 4mo agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted
- 4mo agoCNXUABBVNVOEOLS+2One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsPR NewswireIn regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one...
- 4mo agoEOLSEvolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin QualityBusiness WireEvolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement
- 5mo agoCNXUIARTEOLSBVS+1Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItPR NewswireUSA News Group News Commentary — Wall Street's regenerative medicine bench just got one name deeper. On May 21, 2026, Conexeu Sciences Inc. (Nasdaq:...
- 5mo agoEOLSEvolus to Participate in The Jefferies Global Healthcare ConferenceBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and
- 6mo agoEOLSEvolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in EuropeBusiness WireEvolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced "esteem"), its
- 6mo agoEOLSEvolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year OutlookBusiness WireGlobal Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025 GAAP Operating Loss of $6.8 Million and Adjusted EBITDA of $0.6 Million for
- 7mo agoEOLSEvolus to Report First Quarter Financial Results on May 4, 2026Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4,
- 7mo agoEOLSTLXTelix Appoints David Gill as Non-Executive DirectorGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED),
- 7mo agoEOLSEvolus to Participate in the Needham 25th Annual Virtual Healthcare ConferenceBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and
- 7mo agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted stock units
- 8mo agoEOLSEvolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026Business WireTotal Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year Delivered GAAP Operating Income of $4.2 Million for the
- 8mo agoEOLSEvolus to Participate in The Leerink Partners Global Healthcare ConferenceBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and
- 8mo agoEOLSEvolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on
- 9mo agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026 of an aggregate of 153,218
- 10mo agoEOLSEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net RevenueBusiness WireProvides 2026 Net Revenue Guidance and Maintains Projection for Full-Year 2026 Profitability1 Preliminary Unaudited Net Revenue of $88.6 Million to $90.6 Million for the Fourth Quarter 2025, Representing 12% to 15%
- 12mo agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate
- 1y agoEOLSEvolus Reports Third Quarter 2025 Financial ResultsBusiness WireTotal Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau® Net Revenue of $63.2 Million for Q3 2025, Up from $59.7 Million in Q2 2025, Reflecting Sequential
- 1y agoEOLSEvolus to Participate in 2025 Stifel Healthcare ConferenceBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and
- 1y agoEOLSEvolus to Report Third Quarter Financial Results on November 5, 2025Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday,
- 1y agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase an aggregate of
- 1y agoEOLSTop Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler LaunchPR NewswireEvolus, Inc. (NASDAQ: EOLS), a leading publicly traded aesthetic beauty company, has named Dr. Benjamin Eskenazi, MD, FACS, founder of Miami Beach's...
- 1y agoEOLSEvolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744
- 1y agoEOLSEvolus Announces the Appointment of Tatjana Mitchell as Chief Financial OfficerBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective
- 1y agoEOLSEvolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic BootcampBusiness WireEvolysse™ Sculpt met the primary endpoint of non-inferiority and demonstrated statistical superiority to Restylane®-Lyft The safety profile was similar between Evolysse™ Sculpt and
- 1y agoEOLSEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel ProductBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA)
- 1y agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August of an aggregate of 12,731 restricted stock units (RSUs) of
- 1y agoEOLSEvolus, Inc. (EOLS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoEOLSEvolus Reports Second Quarter 2025 Financial Results and Provides Business UpdatesBusiness WireGlobal Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decreased; Growth Driven by the Successful Launch of Evolysse™ and Continued Strength in
- 1y agoEOLSEvolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading NeurotoxinsBusiness WireFirst head-to-head study of four United States (U.S.) Food & Drug Administration (FDA) approved neurotoxins: Jeuveau®, Botox®, Dysport®, and Xeomin® The study published in JAMA Dermatology
- 1y agoEOLSEvolus to Report Second Quarter Financial Results on August 5, 2025Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday,
- 1y agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of
- 1y agoEOLSEvolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in FranceBusiness WireLaunching into this key growth market1 as part of the company's geographic expansion strategy Evolus to provide Nuceiva® to French medical aesthetics healthcare professionals through its partnership with
- 1y agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of
- 1y agoEOLSEvolysse™ Recognized in 2025 Shape Skin AwardsBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin
- 1y agoEOLSEvolus Announces Departure of its Chief Financial OfficerBusiness WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June
- 1y agoEOLSEvolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid GelsBusiness WireData showed that both Evolysse™ Form and Evolysse™ Smooth met the primary endpoint of non-inferiority1 and demonstrated statistical superiority1 to Restylane®-L, the control product The study
- 1y agoEOLSEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of non-qualified stock options to purchase an aggregate of
- 1y agoEOLSEvolus Reports First Quarter 2025 ResultsBusiness WireGlobal Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating